Literature DB >> 28118218

Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?

Mordechai Grupper1, David P Nicolau.   

Abstract

PURPOSE OF REVIEW: Skin and soft tissue infections (SSTIs) are prevalent in the obese population, with rising trend expected. Although numerous antibiotics are available for the prevention and treatment of SSTIs, their characterization in obese patients is not a regulatory mandate. Consequently, information that carries importance for optimizing the dosing regimen in the obese population may not be readily available. This review focuses on the most recent pharmacokinetic and pharmacodynamic data on this topic with attention to cefazolin for surgical prophylaxis as well as antibiotics that are active against methicillin-resistant Staphylococcus aureus (MRSA). Moreover, the implications for optimizing SSTIs prevention and treatment in the obese population will also be discussed. RECENT
FINDINGS: On the basis of pharmacokinetic/pharmacodynamic considerations, most studies found a perioperative prophylactic cefazolin regimen of 2 g to be reasonable in the case of obese patients undergoing cesarean delivery or bariatric surgery. There is general paucity of data regarding the pharmacokinetic/pharmacodynamic characteristics of antimicrobials active against MRSA in obese patients, especially for the target tissue. Therapeutic drug monitoring has been correlated with pharmacokinetic/pharmacodynamic optimization for vancomycin and teicoplanin, and should be used in these cases. There is more supportive evidence for the use of oxazolidinones (linezolid and tedizolid), daptomycin and lipoglycopeptides (telavancin, dalbavancin and oritavancin) in the management of SSTIs in this population.
SUMMARY: The pharmacokinetic/pharmacodynamic approach, which can be used as a basis or supplement to clinical trials, provides valuable data and decision-making tools for optimizing regimens used for both prevention and treatment of SSTIs in the obese population. Important pharmacokinetic/pharmacodynamic characteristics of antibiotics, such as the penetration into the subcutaneous tissue and the probability of reaching the pharmacodynamic, target dictate efficacy, and thus should be taken into account and further investigated.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28118218     DOI: 10.1097/QCO.0000000000000356

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

Review 1.  Review of the Applications of Biomedical Compositions Containing Hydroxyapatite and Collagen Modified by Bioactive Components.

Authors:  Agnieszka Sobczak-Kupiec; Anna Drabczyk; Wioletta Florkiewicz; Magdalena Głąb; Sonia Kudłacik-Kramarczyk; Dagmara Słota; Agnieszka Tomala; Bożena Tyliszczak
Journal:  Materials (Basel)       Date:  2021-04-21       Impact factor: 3.623

2.  Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections.

Authors:  Alison L Blackman; Praneeth Jarugula; David P Nicolau; Sai Ho Chui; Manjari Joshi; Emily L Heil; Mathangi Gopalakrishnan
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.

Authors:  Joaquim F Monteiro; Siomara R Hahn; Jorge Gonçalves; Paula Fresco
Journal:  Pharmacol Res Perspect       Date:  2018-07

4.  Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.

Authors:  Wanhong Wu; Meng Ke; Lingling Ye; Cuihong Lin
Journal:  Eur J Clin Pharmacol       Date:  2021-01-15       Impact factor: 2.953

5.  Safety and Effectiveness of High-Dose Cefazolin in Patients With High Body Weight: A Retrospective Cohort Study.

Authors:  HaYoung Ryu; Sana Mohayya; Thomas Hong; Mansi Modi; Jaehee Yang; Ahmed Abdul Azim; Pinki J Bhatt; Luigi Brunetti; Navaneeth Narayanan
Journal:  Open Forum Infect Dis       Date:  2022-02-28       Impact factor: 3.835

6.  Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis.

Authors:  Christoph Dorn; David Petroff; Alexander Kratzer; Frieder Kees; Charlotte Kloft; Markus Zeitlinger; Hermann Wrigge; Philipp Simon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-08-09       Impact factor: 2.569

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.

Authors:  Matthew William McCarthy
Journal:  Clin Pharmacokinet       Date:  2021-07-13       Impact factor: 5.577

8.  Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis.

Authors:  Rodrigo M Carrillo-Larco; Cecilia Anza-Ramírez; Giancarlo Saal-Zapata; David Villarreal-Zegarra; Jessica Hanae Zafra-Tanaka; Cesar Ugarte-Gil; Antonio Bernabé-Ortiz
Journal:  J Epidemiol Community Health       Date:  2021-07-29       Impact factor: 3.710

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.